ICON Public Company (ICLR) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue was $2,001.3 million, down 4.3% year-over-year, reflecting a transitional period with elevated cancellations and delays in clinical trial starts, especially in biotech and large pharma segments.

• Adjusted EBITDA margin was 19.5%, better than expected due to strong cost controls and operational alignment, despite revenue headwinds.

• Full-year guidance was revised downward by $400 million at the midpoint, mainly due to the removal of two next-generation COVID trials ($350 million impact) and continued elevated cancellations.

• Strategic partnerships, laboratory services, and early-phase business showed growth, with new awards and expanded relationships in large pharma.

• $250 million in share repurchases executed in Q1, with continued emphasis on buybacks and selective M&A supported by a strong balance sheet.

Financial highlights

• Q1 revenue: $2,001.3 million, down 4.3% year-over-year (down 3.2% constant currency).

• Adjusted EBITDA: $390.7 million (19.5% margin), down from $444.0 million (21.2% margin) in Q1 2024.

• Adjusted net income: $258.3 million (12.9% margin), adjusted EPS: $3.19, down from $3.47 in Q1 2024.

• US GAAP net income: $154.2 million ($1.90 per diluted share), down from $2.25 per share in Q1 2024.

• Free cash flow: $239.3 million; cash and equivalents: $526.7 million at March 31, 2025; net debt: $2.9 billion; leverage ratio: 1.7x.

Outlook and guidance

• Full-year 2025 revenue guidance updated to $7,750–$8,150 million, a decrease of 6.4% to 1.6% year-over-year.

• Adjusted diluted EPS guidance for 2025 set at $12.75–$14.25, compared to $14.00 in 2024.

• Guidance excludes two large next-generation COVID vaccine trials, though one may resume; assumes continued elevated cancellation rates and stable burn rate.

• EBITDA margin expected to be about 1% lower than prior year, with gradual improvement through the year and exit rate near 21%.

• FX expected to be a modest tailwind (~1%) for the full year; capital expenditure expected to be around $200 million.